BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:30 PM
 | 
Mar 30, 2010
 |  BC Extra  |  Company News

NICE backs narrowed Multaq use

The U.K.'s NICE issued a second preliminary appraisal recommending the limited use of Multaq dronedarone from sanofi-aventis Group (Euronext:SAN; NYSE:SNY) as second-line therapy for non-permanent atrial fibrillation in patients with additional cardiovascular risk...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >